Bifidobacteriumlongum subsp. infantis CECT7210 (B. infantis IM-1®) Displays In Vitro Activity against Some Intestinal Pathogens
- 2020-10-24
- Nutrients 12(11)
- L. Ruiz
- A. Flórez
- B. Sánchez
- J. A. Moreno-Muñoz
- M. Rodriguez-Palmero
- J. Jiménez
- C. G. D. L. R. Gavilán
- M. Gueimonde
- P. Ruas-Madiedo
- A. Margolles
- PubMed: 33114404
- DOI: 10.3390/nu12113259
Abstract
Certain non-digestible oligosaccharides (NDO) are specifically fermented by bifidobacteria along the human gastrointestinal tract, selectively favoring their growth and the production of health-promoting metabolites. In the present study, the ability of the probiotic strain Bifidobacterium longum subsp. infantis CECT7210 (herein referred to as B. infantis IM-1®) to utilize a large range of oligosaccharides, or a mixture of oligosaccharides, was investigated. The strain was able to utilize all prebiotics screened. However, galactooligosaccharides (GOS), and GOS-containing mixtures, effectively increased its growth to a higher extent than the other prebiotics. The best synbiotic combination was used to examine the antimicrobial activity against Escherichia coli, Cronobacter sakazakii, Listeria monocytogenes and Clostridium difficile in co-culture experiments. C. difficile was inhibited by the synbiotic, but it failed to inhibit E. coli. Moreover, Cr. sakazakii growth decreased during co-culture with B. infantis IM-1®. Furthermore, adhesion experiments using the intestinal cell line HT29 showed that the strain IM-1® was able to displace some pathogens from the enterocyte layer, especially Cr. sakazakii and Salmonella enterica, and prevented the adhesion of Cr. sakazakii and Shigella sonnei. In conclusion, a new synbiotic (probiotic strain B. infantis IM-1® and GOS) appears to be a potential effective supplement for maintaining infant health. However, further studies are needed to go more deeply into the mechanisms that allow _B._infantis IM-1® to compete with enteropathogens.
Keywords: Bifidobacterium longum; enteropathogens; prebiotics; probiotics; synbiotic.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Bifidobacterium infantis | Prevented Shigella sonnei Adhesion | Beneficial | Moderate |
Bifidobacterium infantis | Reduced Clostridium difficile Infection | Beneficial | Moderate |
Bifidobacterium infantis | Reduced Colonization of Cronobacter sakazakii in Enterocytes | Beneficial | Moderate |
Bifidobacterium infantis | Reduced Cronobacter sakazakii Adhesion | Beneficial | Moderate |
Bifidobacterium infantis | Reduced Enterocyte Layer Colonization by Salmonella enterica | Beneficial | Moderate |
Bifidobacterium infantis | Reduced Growth of Cronobacter sakazakii | Beneficial | Moderate |
Bifidobacterium infantis BI02 | Prevented Shigella sonnei Adhesion | Beneficial | Moderate |
Bifidobacterium infantis BI02 | Reduced Clostridium difficile Infection | Beneficial | Moderate |
Bifidobacterium infantis BI02 | Reduced Colonization of Cronobacter sakazakii in Enterocytes | Beneficial | Moderate |
Bifidobacterium infantis BI02 | Reduced Enterocyte Pathogen Load | Beneficial | Moderate |
Bifidobacterium infantis BI02 | Reduced Growth of Cronobacter sakazakii | Beneficial | Moderate |
Bifidobacterium infantis M-63 | Reduced Clostridium difficile Count | Beneficial | Large |
Bifidobacterium infantis M-63 | Reduced Growth of Cronobacter sakazakii | Beneficial | Moderate |
Bifidobacterium infantis MAK22B04I | Reduced Clostridium difficile Infection | Beneficial | Moderate |
Bifidobacterium infantis MAK22B04I | Reduced Growth of Cronobacter sakazakii | Beneficial | Moderate |
Bifidobacterium infantis SD-6720 | Reduced Clostridium difficile Infection | Beneficial | Moderate |
Bifidobacterium infantis SD-6720 | Reduced Enteropathogen Adhesion | Beneficial | Moderate |
Bifidobacterium infantis SD-6720 | Reduced Enteropathogen Colonization | Beneficial | Moderate |
Bifidobacterium infantis SD-6720 | Reduced Growth of Cronobacter sakazakii | Beneficial | Moderate |
Bifidobacterium infantis VPro 53 | Increased Bifidobacteria Growth | Beneficial | Large |
Bifidobacterium infantis VPro 53 | Reduced Clostridium difficile Infection | Beneficial | Moderate |
Bifidobacterium infantis VPro 53 | Reduced Enteropathogen Presence in Enterocyte Layer | Beneficial | Large |
Bifidobacterium infantis VPro 53 | Reduced Growth of Cronobacter sakazakii | Beneficial | Moderate |
Bifidobacterium longum subsp. infantis | Reduced Clostridium difficile Infection | Beneficial | Moderate |
Bifidobacterium longum subsp. infantis | Reduced Growth of Cronobacter sakazakii | Beneficial | Moderate |